Expression of inflammatory cytokines and Fas in alveolar macrophages from ARDS patients
ARDS患者肺泡巨噬细胞炎症细胞因子和Fas的表达
基本信息
- 批准号:10671438
- 负责人:
- 金额:$ 1.92万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1998
- 资助国家:日本
- 起止时间:1998 至 1999
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The objective of this study was to evaluate the role of inducible nitric oxide synthase (iNOS) and proinflammatory cytokines together with apoptosis related factors in alveolar macrophages (AMs) in the pathogenesis of acute respiratory distress syndrome (ARDS) following sepsis. To investigate these expressions in AMs collected from ARDS patients following sepsis, the expression of iNOS and IL-1□,IL-6,IL-8 in AMs were determined by the immunofluorescent technique. The level of NOx, IL-1□,IL-6,and IL-8 in bronchoalveolar lavage fluid (BALF) supernatant and in serum were measured concurrently. To exclude the effect of the long-term ventilation, sepsis syndrome alone, and/or the administration of sedative drugs, all data obtained from patients with ARDS following sepsis were compared with the data from normal control subjects and from septic patients who had been mechanically ventilated for one week without fulfilling the criteria of ARDS (LTV group). Using immunofluorescent technique, our study identified the strong expression of iNOS in AMs of human lungs predominantly at the early stage of ARDS following sepsis. Whereas no expression of iNOS was observed in AMs from the control group, nor was observed in AMs from the LTV group. Another finding of this study is the marked increase of IL-6 and IL-8 levels in BALF supernatant and the serum from patients with ARDS as compared with the control and the LTV group. Also, statistically significant elevations were detected in NOx, IL-6 and IL-8 levels in BALF supernatant from the ARDS group compared with the control group. The result suggests that iNOS together with proinflammatory cytokines produced by AMs might play a pivotal role in the pathogenesis of acute lung injury and be useful for monitoring disorders in the lung of patients with ARDS following sepsis.
本研究旨在探讨诱导型一氧化氮合酶(iNOS)、促炎细胞因子和凋亡相关因子在脓毒症后急性呼吸窘迫综合征(ARDS)发病机制中的作用。为了研究脓毒症后急性呼吸窘迫综合征患者AM中这些表达,采用免疫荧光技术检测AM中iNOS和IL-1、IL-6、IL-8的表达。同时检测支气管肺泡灌洗液(BALF)上清液和血清中NOx、IL-1、IL-6和IL-8的水平。为了排除长期通气、脓毒症综合征和/或镇静药物给药的影响,将脓毒症后ARDS患者的所有数据与正常对照组和机械通气1周但不符合ARDS标准的脓毒症患者(LTV组)的数据进行比较。本研究应用免疫荧光技术检测了诱导型一氧化氮合酶在脓毒症后急性呼吸窘迫综合征(ARDS)早期肺泡巨噬细胞中的强表达。对照组AM中未见iNOS表达,LTV组AM中亦未见iNOS表达。本研究的另一个发现是,与对照组和LTV组相比,ARDS患者BALF上清液和血清中IL-6和IL-8水平显著升高。与对照组相比,ARDS组BALF上清液中NOx、IL-6和IL-8水平也显著升高。结果提示,诱导型一氧化氮合酶和AM产生的促炎细胞因子在脓毒症后急性肺损伤的发病机制中起重要作用,对监测脓毒症后ARDS患者的肺功能紊乱具有重要意义。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
橋本 悟: "ARDS発症における最近の病態解明と治療方法の動向"外科治療. 83. 187-192 (2000)
Satoru Hashimoto:“ARDS 发展中的最新病理学阐明和治疗方法趋势”Surgical Treatment。 83. 187-192 (2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ernst EJ: "Effects of antibiotics in a rat model"Antimicrob Agent : Chemother. 43(10). 2389-2394 (1999)
Ernst EJ:“抗生素对大鼠模型的影响”抗菌剂:Chemother。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kobayashi A: "Expression of iNOS and inflammatory cytokines in alvedar macrophge"Chest. 113. 1632-1639 (1998)
Kobayashi A:“iNOS 和炎性细胞因子在肺泡巨噬细胞中的表达”胸部。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hashimoto S, Kobayashi A, et al.: "Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome"Am J Respir Grit Care Med. 161. 237-243 (2000)
Hashimoto S、Kobayashi A 等人:“脓毒症急性呼吸窘迫综合征中穿孔素/颗粒酶和 FasL/Fas 两种死亡途径的上调”Am J Respir Grit Care Med。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
橋本悟: "急性肺傷害時のPerforin/Granzyhu.FasL/Fas系の遺伝子発現" 日本呼吸器学会. (発表予定).
Satoru Hashimoto:“急性肺损伤期间穿孔素/Granzyhu.FasL/Fas 系统的基因表达”日本呼吸学会(已安排演示)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YAMASHITA Tomomitsu其他文献
YAMASHITA Tomomitsu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 1.92万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 1.92万 - 项目类别: